NeuroPace (NPCE) 44th Annual J.P. Morgan Healthcare Conference summary

Mission and Strategic Positioning

• Focused on transforming lives of epilepsy patients by reducing or eliminating seizures, guided by a strong sense of stewardship and a highly skilled team.

• Positioned for both near-term and long-term growth, leveraging best-in-class technology, data, and team.

• RNS System enables individualized therapy through continuous monitoring and tailored stimulation, creating a unique dataset.

• RNS System is the only closed-loop, brain-responsive neuromodulation device with real-time iEEG monitoring and personalized therapy.

• Over 8,000 patients have received the RNS System, with a $3.5B+ annual target market opportunity and 20%+ long-range plan growth.

Financial Performance and Guidance

• Achieved $100 million in annual revenue for the first time in 2025, with 25% year-on-year growth and gross margin of 77.2%.

• Core RNS System revenue reached $81.7 million, also at 25% growth.

• FY26 revenue guidance is $98–$100 million, with RNS revenue growth of 20–22% and gross margin of 81–82%.

• DIXI Medical will be reported as a discontinued operation starting Q1 2026; guidance excludes Dixie and new indications.

• Achieved positive cash flow in Q4 2025; on track for cash flow break-even by 2027.

Commercial Execution and Market Expansion

• Achieved record highs in prescribers and implanters, with rising utilization rates.

• Expanded beyond Level 4 centers into community settings, supported by Project CARE, targeting 1,800 additional epileptologists and neurosurgeons.

• Project CARE increases access in Level 3 and community centers, building referral networks and preparing for indication expansion.

• Strengthened patient funnel management and onboarding processes for new centers.

• Growth initiatives include clinical development, product innovation, and market expansion through sales force and direct-to-patient marketing.